NCT05475106 is a EARLY_PHASE1 clinical trial of Neoantigen Peptides in Neoplasms, sponsored by Instituto de Medicina Regenerativa.

Who is sponsoring NCT05475106?

NCT05475106 is sponsored by Instituto de Medicina Regenerativa.

What drugs are being tested in NCT05475106?

Interventions in NCT05475106: Neoantigen Peptides.

Is NCT05475106 still recruiting?

NCT05475106 is currently recruiting now. Last updated 6 March 2024.

Last reviewed 2024-03-06 · How we verify

NCT05475106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

Recruiting now EARLY_PHASE1 Last updated 6 March 2024

What this trial tests

EARLY_PHASE1 trial testing Neoantigen Peptides in Neoplasms in 100 participants. Currently enrolling.

Timeline

12 May 2022

Primary endpoint
25 November 2025

20 June 2026

Quick facts

Lead sponsor	Instituto de Medicina Regenerativa
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	12 May 2022
Primary completion	25 November 2025
Estimated completion	20 June 2026
Sites	1 location across Mexico

Drugs / interventions tested

Neoantigen Peptides — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Instituto de Medicina Regenerativa — full company profile →

Who can join

16 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigen cancer vaccines: a new star on the horizon.
Li X, You J, Hong L, Liu W, et al · · 2023 · cited 31× · PMID 38164734 · DOI 10.20892/j.issn.2095-3941.2023.0395
Cancer Vaccines in the Immunotherapy Era: Promise and Potential.
Verma C, Pawar VA, Srivastava S, Tyagi A, et al · · 2023 · cited 21× · PMID 38140187 · DOI 10.3390/vaccines11121783
Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor.
Xie YJ, Liu WQ, Li D, Hou JC, et al · · 2023 · cited 13× · PMID 36851271 · DOI 10.3390/vaccines11020394
Biomaterials nanoplatform-based tumor vaccines for immunotherapy.
Li Z, Zhang H, Gong Q, Luo K. · · 2025 · cited 10× · PMID 40678264 · DOI 10.1016/j.bioactmat.2025.06.038
Cancer Nanovaccines: Mechanisms, Design Principles, and Clinical Translation.
Zaccariotto GC, Bistaffa MJ, Zapata AMM, Rodero C, et al · · 2025 · cited 8× · PMID 40202241 · DOI 10.1021/acsnano.4c15765
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.
Chekaoui A, Garofalo M, Gad B, Staniszewska M, et al · · 2024 · cited 8× · PMID 39720956 · DOI 10.1007/s10238-024-01541-7
The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.
Kye Y, Nagineni L, Gadad S, Ramirez F, et al · · 2022 · cited 7× · PMID 36077792 · DOI 10.3390/cancers14174255
Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer.
Shah BA, Holden JA, Lenzo JC, Hadjigol S, et al · · 2025 · cited 6× · PMID 40204832 · DOI 10.1038/s41541-025-01118-9

Verify or expand the search:

Other trials of Neoantigen Peptides

Trials testing the same drug.

NCT04509167 — Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms · EARLY_PHASE1 · completed

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Instituto de Medicina Regenerativa trials

Trials by the same sponsor.

NCT04509167 — Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms · EARLY_PHASE1 · completed
NCT04456361 — Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 · EARLY_PHASE1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05475106 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto de Medicina Regenerativa
Last refreshed: 6 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05475106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing